Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The effect of adenovirus-mediated siRNA targeting BMPR-II on UHMWPE-induced osteoclast formation.

Wang Y, Wu NN, Mu YQ, Zhang RX, Hu M, Li RD, Chen L, He BC, Deng ZL.

Biomaterials. 2013 Jan;34(1):150-9. doi: 10.1016/j.biomaterials.2012.09.059. Epub 2012 Oct 15.

PMID:
23079666
2.

Inhibitory effect of adenovirus-mediated siRNA-targeting BMPR-IB on UHMWPE-induced bone destruction in the murine air pouch model.

Wang Y, Wu NN, Hu M, Mou YQ, Li RD, Chen L, He BC, Deng ZL.

Connect Tissue Res. 2012;53(6):528-34. doi: 10.3109/03008207.2012.702817. Epub 2012 Jul 24.

PMID:
22827452
3.

Inhibition of osteoclastogenesis by RNA interference targeting RANK.

Ma R, Xu J, Dong B, Kauther MD, Jäger M, Wedemeyer C.

BMC Musculoskelet Disord. 2012 Aug 22;13:154. doi: 10.1186/1471-2474-13-154.

4.

Adenovirus-mediated siRNA targeting CXCR2 attenuates titanium particle-induced osteolysis by suppressing osteoclast formation.

Wang C, Liu Y, Wang Y, Li H, Zhang RX, He MS, Chen L, Wu NN, Liao Y, Deng ZL.

Med Sci Monit. 2016 Mar 4;22:727-35.

5.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

6.

Coenzyme q10 regulates osteoclast and osteoblast differentiation.

Moon HJ, Ko WK, Jung MS, Kim JH, Lee WJ, Park KS, Heo JK, Bang JB, Kwon IK.

J Food Sci. 2013 May;78(5):H785-891. doi: 10.1111/1750-3841.12116. Epub 2013 Apr 12.

PMID:
23582186
7.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
8.

Inhibiting wear particles-induced osteolysis with doxycycline.

Zhang C, Tang TT, Ren WP, Zhang XL, Dai KR.

Acta Pharmacol Sin. 2007 Oct;28(10):1603-10.

11.

Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation.

Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F, Peterlik M, Pietschmann P.

J Biomed Mater Res A. 2006 Apr;77(1):75-83.

PMID:
16355411
12.

Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model.

Córdova LA, Trichet V, Escriou V, Rosset P, Amiaud J, Battaglia S, Charrier C, Berreur M, Brion R, Gouin F, Layrolle P, Passuti N, Heymann D.

Acta Biomater. 2015 Feb;13:150-8. doi: 10.1016/j.actbio.2014.10.042. Epub 2014 Nov 20.

PMID:
25462844
13.

Inhibitory effects of osteoprotegerin on osteoclast formation and function under serum-free conditions.

Fu YX, Gu JH, Zhang YR, Tong XS, Zhao HY, Yuan Y, Liu XZ, Bian JC, Liu ZP.

J Vet Sci. 2013;14(4):405-12. Epub 2013 Jun 30.

14.

Pyrroloquinoline quinine inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos in mouse bone marrow cells and inhibits wear particle-induced osteolysis in mice.

Kong L, Yang C, Yu L, Smith W, Zhu S, Zhu J, Zhu Q.

PLoS One. 2013 Apr 17;8(4):e61013. doi: 10.1371/journal.pone.0061013. Print 2013.

15.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
16.

Inhibitory effects of recombinant IL-4 and recombinant IL-13 on UHMWPE-induced bone destruction in the murine air pouch model.

Wang Y, Wu NN, Mou YQ, Chen L, Deng ZL.

J Surg Res. 2013 Apr;180(2):e73-81. doi: 10.1016/j.jss.2012.04.016. Epub 2012 Apr 28.

PMID:
22560858
17.

Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.

Häusler KD, Horwood NJ, Chuman Y, Fisher JL, Ellis J, Martin TJ, Rubin JS, Gillespie MT.

J Bone Miner Res. 2004 Nov;19(11):1873-81. Epub 2004 Aug 16.

19.

Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.

Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC.

J Cell Physiol. 2005 Jun;203(3):573-82.

PMID:
15573398
20.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031. Epub 2011 Sep 9.

PMID:
21925296

Supplemental Content

Support Center